Company Overview
Tango Therapeutics is a biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer.
Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer.
This includes expanding the universe of precision oncology targets into novel areas such as tumor suppressor gene loss and their contribution to the ability of cancer cells to evade immune cell killing.
The Tango labs and offices are located at 201 Brookline Avenue, in the Fenway area of Boston, Massachusetts
Summary
In this newly opened position at Tango, you will collaboratively manage a global clinical trial though the development of a novel drug. You will bring robust trail management experience, with strong communication, vendor management and project management skills. You will develop an understanding of the needs of the many teams necessary to do comprehensive clinical operations work, with a collaborative outlook. You will manage workloads to meet expedited project timelines in a rapid and dynamic environment.
Your Role:
- You will manage clinical trials from start-up through close-out to ensure both internal and external deliverables are on time and on budget while facilitating collaboration across functional areas
- Work with the cross functional clinical team to coordinate the relevant and timely exchange of information/materials to support clinical trial delivery and execution
- Oversee and contribute to the development of clinical trial project timelines and ensure communication and understanding of risks/challenges; establish plans and monitor metrics; ensure that timelines are accurate and comprehensive
- Proactively manage clinical trial outsourced partners, including identification of risk, to ensure trial deliverables and performance goals are met
- Manage the day-to-day contact with CRO counterpart; daily review and identification of potential issues or problems with sites and communicate/escalate to clinical team as necessary
- Collaborate with the CRO to keep clinical study database current and accurate
- Proactively manage and track project scope and change orders, for clinical trial operations
- Additional duties and responsibilities as required
What You Bring:
- Bachelor’s degree in Life Sciences or a related healthcare discipline (e.g., Nursing, Medical Technology, or Laboratory Sciences)
- Minimum of 5 years of relevant industry experience, with a strong focus on clinical operations
- Demonstrated experience operating within a global drug development organization
- Proven experience contributing to global study start-up and providing input into protocol and study design
- Experience working effectively within a complex, matrixed organizational environment
- Prior experience operating within a full-service outsourcing (FSO) model
- Strong experience in sponsor oversight, including oversight of CROs and site management activities
- End-to-end clinical trial experience, from study start-up through close-out
- Experience supporting the execution of late-phase and/or pivotal clinical trials
- Experience preparing for and supporting regulatory authority inspections
- Demonstrated ability to manage and oversee global studies across multiple geographic regions
- Experience identifying operational risks and proactively implementing mitigation strategies
We are an equal opportunity employer and value diversity at our company. We do not discriminate on the basis of race, religion, color, national origin, gender, sexual orientation, age, marital status, veteran status, or disability status.
#LI-HYBRID
What We Do
Tango Therapeutics is a biotechnology company discovering and developing novel medicines targeting cancer vulnerabilities to deliver transformational new therapies for patients. Tango was launched in 2017 with a $55 million Series A investment from Third Rock Ventures. The company has established a robust product engine that leverages advances in DNA sequencing and CRISPR-based target discovery to generate breakthrough medicines that have the potential to provide deeper, more sustained benefit than today’s targeted therapies, and extend the benefit of available immuno-oncology agents. Tango Therapeutics is focused on three areas of drug development, each in well-defined patient populations currently lacking effective treatment options, and each with hallmarks of cancer that have not been targeted yet. These include: loss of tumor suppressor gene function; multiple oncogenic drivers; and immune evasion. What fuels each of Tango’s programs is an increasingly sophisticated ability to utilize synthetic lethality - the interaction between two genes that causes cell death when both are inactivated. In cancer cells, one of these genes is inactivated by mutation; the other will be inactivated by a drug. This approach leaves normal cells largely unaffected, with the potential to greatly enhance anti-tumor efficacy and reduce associated toxicity. Tango’s success will be driven by its depth of understanding of the genetic subtypes of cancer, and corresponding insights into novel drug targets and combinations uniquely relevant to each subtype. By shaping discovery efforts in this way, Tango has the potential to reach the clinic quickly, and with a clear plan for identifying the patients most likely to benefit from each new treatment, an approach that could increase both speed and probability of success in translating novel target discoveries into transformational new medicines for patients.
